Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

Diffuse Large B Cell Lymphoma Clinical Trial

— COPA-R-CHOP  

Official title:

A Prospective Multicenter Phase 2 Study of Copanlisib in Combination With Rituximab and CHOP Chemotherapy (COPA-R-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04263584
• Other study ID #: UKM18-0021
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 19, 2020
• Est. completion date: April 2025

Study information

• Verified date: January 2024
• Source: University Hospital Muenster
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multicenter, non-randomized, open-label, phase II study to describe the efficacy of R-CHOP plus copanlisib including a safety run-in phase in order to detect early and common unexpected toxicities caused by the addition of copanlisib to the standard immuno-chemotherapy R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL)

Description:

Patients diagnosed with DLBCL can be cured with a combined approach of CHOP chemotherapy and the anti-CD20 antibody rituximab in roughly 65% of cases. About one third of patients with DLBCL relapse or show primary progressive disease after modern first-line therapy. The outcome of these patients is poor in particular if first-line therapy contained rituximab. Novel therapeutic approaches are urgently warranted. Thus, it is the goal to further improve progression-free Survival (PFS) and overall Survival (OS) by combining R-CHOP with copanlisib. Copanlisib is a small molecule pan-class 1 PI3K inhibitor and approved by US FDA for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 62
• Est. completion date: April 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Histologically confirmed

1. DLBCL (NOS) or

2. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or

3. High-grade B-cell lymphoma (NOS)

4. Follicular lymphoma Grade 3B (primary diagnosis without history of indolent lymphoma) with a diagnostic biopsy performed within 3 months before study entry and with material available for central review and complimentary scientific analyses

2. 18-80 years of age

3. International Prognostic Index (IPI) 2-5

4. Eastern Cooperative Oncology Group Performance status (ECOG) 0-2

5. Life expectancy of at least 3 months

6. Women of childbearing potential and men must agree to use effective contraception when sexually active. This applies for the time period between signing of the informed consent form and 6 months after the last administration of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%), e.g. intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner and sexual abstinence. The use of condoms by male patients is required unless the female partner is permanently sterile.

Adequate baseline laboratory values collected no more than 7 days before starting study treatment:

7. Total bilirubin = 1.5 x ULN (< 3 x ULN for patients with Gilbert syndrome, patients with cholestasis due to compressive adenopathies of the hepatic hilum or documented liver involvement or with biliary obstruction due to lymphoma)

8. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN (= 5 x ULN for patients with liver involvement by lymphoma)

9. Lipase = 1.5 x ULN

10. Glomerular filtration rate (GFR) = 40 mL/min/1.73 m2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. If not on target, this evaluation may be repeated once after at least 24 hours either according to the CKD-EPI formula or by 24-hour sampling. If the later result is within acceptable range, it may be used to fulfill the inclusion criteria instead.

11. INR and PTT = 1.5 x ULN

12. Platelet count = 75,000 /mm3.

13. Hemoglobin (Hb) = 8 g/dL

14. Absolute neutrophil count (ANC) = 1,500/mm3

15. Left ventricular ejection fraction = 50%

16. No prior lymphoma therapy

17. Ability to understand and willingness to sign written informed consent. Signed informed consent must be obtained before any study specific procedure.

Exclusion Criteria:

Patients who meet any of the following criteria at the time of screening will be excluded.

1. Previous assignment to treatment during this study. Patients permanently withdrawn from study participation will not be allowed to re-enter the study.

2. Previous (within 28 days or less than 5 half-lives of the drug before start of study treatment) or concomitant participation in another clinical study with investigational medicinal product(s).

3. Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent persons (e.g. employee or student of the investigational site).

Excluded medical conditions:

4. Type I or II diabetes mellitus with HbA1c > 8.5% at screening or fasting plasma glucose > 160 mg/dL at screening

5. History or concurrent condition of interstitial lung disease and/or severely impaired lung function (as judged by the investigator)

6. Known lymphoma involvement of the central nervous system

7. Human immunodeficiency virus (HIV) infection

8. Hepatitis B (HBV) and C (HCV) infection. Patients with serologic markers of HBV immunization due to vaccination (HBsAg negative, Anti-HBc negative and Anti-HBs positive) will be eligible

9. CMV-PCR positive at baseline

10. Previous or concurrent history of malignancies within 5 years prior to study treatment except for curatively treated:

1. Cervical carcinoma in situ

2. Non-melanoma skin cancer

3. Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])

4. Localized prostate cancer

11. Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to the start of study medication

12. Patients with seizure disorder requiring medication

13. Proteinuria of = CTCAE Grade 3 as assessed by a 24h protein quantification or estimated by urine protein: creatinine ratio > 3.5 on a random urine sample

14. Concurrent diagnosis of pheochromocytoma

15. Congestive heart failure > New York Heart Association (NYHA) class 2

16. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)

17. Myocardial infarction less than 6 months before start of test drug

18. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication

19. Non-healing wound, ulcer, or bone fracture

20. Active, clinically serious infections > CTCAE Grade 2

21. Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)

22. Known history of drug induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver or portal hypertension

23. Ongoing inflammatory bowel disease

24. History of, or current autoimmune disease

25. Prior treatment with PI3K inhibitors

26. Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent

27. Patient is pregnant (ß-HCG positive) or breast-feeding

28. Known hypersensitivity to copanlisib or to any of the excipients of rituximab, cyclophosphamide, doxorubicine, vincristine, and/or prednisone

Related Conditions & MeSH terms

• Diffuse Large B Cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• Copanlisib
Copanlisib vials 60 mg
• R-CHOP Chemotherapy
Immunochemotherapy

Locations

Country	Name	City	State
Germany	University Hospital RWTH Aachen	Aachen
Germany	Klinikum-Bremen-Mitte	Bremen
Germany	St.-Johannes-Hospital Dortmund	Dortmund
Germany	Onkozentrum Dresden	Dresden
Germany	University Hospital Halle	Halle (Saale)
Germany	Westpfalz-Klinikum	Kaiserslautern
Germany	ÜBAG MVZ Dr. Vehling-Kaiser GmbH	Landshut
Germany	University Hospital Leipzig	Leipzig
Germany	University Hospital Muenster	Muenster
Germany	Hospital of the Ludwig-Maximilians-University (LMU) Munich	Munich
Germany	Hospital Stuttgart - Stuttgart Cancer Center	Stuttgart
Germany	University Hospital Ulm	Ulm

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Muenster	Bayer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2-year progression-free survival	Length of time that a patient lives without disease progression or relapse.	From the day of inclusion into the study until event (disease progression, relapse, death due to any other cause) occurs, assessed up to 4 years.
Secondary	Overall survival	The percentage of patients in this study who are still alive.	From the day of inclusion into the study to death due to any cause, assessed up to 4 years.
Secondary	Event-free survival	Length of time that a patient remains free of certain events (disease progression, start of additional, unplanned antitumor therapy, relapse, death due to any other cause).	From the day of inclusion into the study until event (disease progression, start of additional, unplanned anti-tumor therapy, relapse, death due to any other cause) occurs, assessed up to 4 years.
Secondary	Rate of complete remission	Rate of complete remission measured as number of complete remissions divided by the number of patients included.	From the day of inclusion into the study until date of complete remission, assessed up to 4 years.
Secondary	Rate of partial remission	Rate of partial remission measured as number of partial remissions divided by the number of patients included.	From the day of inclusion into the study until date of partial remission, assessed up to 4 years.
Secondary	Overall response rate	Overall response rate measured as number of complete and partial remissions divided by the number of patients included.	From the day of inclusion into the study until date of complete or partial remission, assessed up to 4 years.
Secondary	Progression rate	Progression rate measured as number of progressions divided by the number of patients included.	From the day of inclusion into the study until date of progression during therapy or within 2 months after last treatment course.
Secondary	Relapse rate	Relapse rate measured as number of relapses divided by the number of patients included.	From the day of inclusion into the study until date of relapse during therapy or within 2 months after last treatment course.
Secondary	Duration of response	The time between the initial response to therapy and subsequent disease progression or relapse.	From documentation of tumor response to relapse, assessed up to 4 years.
Secondary	Adverse events and serious adverse events	Frequency of adverse events and serious adverse events	The documentation of adverse events, including serious adverse events, starts with first study treatment after patient inclusion and ends 100 days after the last application of copanlisib or any component of R-CHOP
Secondary	Rate of treatment-related deaths	The number of deaths during therapy or up to 2 months after the end of therapy divided by the number of patients included.	From the start of therapy up to 2 months after the end of therapy.
Secondary	Therapy cycles (number)	Number of therapy cycles	From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years.
Secondary	Therapy cycles (duration)	Duration of therapy cycles	From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years.
Secondary	Used drugs	Cumulative doses of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) and copanlisib.	From the start of therapy (copanlisib and R-CHOP) until the end of therapy (last application of copanlisib or any component of R-CHOP), assessed up to 0.5 years.
Secondary	Outcome according to lymphoma biology	Lymphoma tissue from all patients will be characterized.	From the start of study until the end of study, assessed up to 4 years.